At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Tauroursodeoxycholic Acid and Doxycyclinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 18 Month, Open Label Study of the Tolerability and Efficacy of a Combination of Doxycycline and Tauroursodeoxycholic Acid (TUDCA) in Patients With Transthyretin Amyloid Cardiomyopathy.
In Brief
A Phase 2 clinical trial evaluating Tauroursodeoxycholic Acid and Doxycycline for Amyloidosis; Heart (Manifestation) and Senile Cardiac Amyloidosis. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The objective of the study is to determine whether the combination of the bile acid TUDCA, and doxycycline will slow the progression of familial and senile amyloidosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartJun 2013
Primary CompletionMay 2015
TodayJul 2026
First PostedMay 16, 2013
Enrollment StartJun 1, 2013
Primary CompletionMay 31, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.1 years ago
Interventions
Tauroursodeoxycholic Acid and Doxycyclinedrug